Marshall Wace
BIIB icon

Marshall Wace’s Biogen BIIB Stock Holding History

Marshall Wace’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$367K Buy
2,000
+1,200
+150% +$221K ﹤0.01% 2589
2025
Q4 		$141K Buy
800
+600
+300% +$98K ﹤0.01% 2663
2025
Q3 		$28K Buy
+200
New +$27K ﹤0.01% 2768

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Marshall Wace's BIIB Position: Q1 2026 in Review

Marshall Wace reduced its Biogen (BIIB) stake by 40% in Q1 2026, selling an estimated $28.8M and leaving 229,879 shares worth $42.1M. The position accounts for 0.04% of the portfolio, ranked #426.

Marshall Wace first reported a position in BIIB in Q3 2014 and has held it in 42 quarters since. The position peaked at $345M in Q4 2022. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Marshall Wace held 229,879 shares of Biogen worth $42.1M as of Q1 2026.
  • Marshall Wace sold 156,049 Biogen shares in Q1 2026, an estimated $28.8M.
  • Biogen made up 0.04% of Marshall Wace's portfolio in Q1 2026, its #426 holding.
  • Marshall Wace first reported a position in Biogen in Q3 2014 and has held it in 42 quarters since.
  • Marshall Wace's Biogen position peaked at $345M in Q4 2022.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.